Our services
We offer a range of products and services, including scientific advice, that help healthcare organizations optimize their operations, improve patient outcomes, and reduce costs. Our target market includes hospitals, health systems, insurance companies, pharmaceutical companies, and government agencies. We focus on serving clients that are looking to improve patient outcomes, reduce costs, and leverage advanced analytics to support their business objectives.
Pharmacovigilance using big data
We help our clients to monitor the effectiveness and safety of medical interventions and medications in the broadly defined patient population as well as specific disease groups with potential drug-drug or drug-disease interactions.
Population health epidemiology and management
We provide analytics solutions to help healthcare organizations manage the health of their patient populations, including identifying at-risk patients, tracking health trends, and developing prevention strategies.
We will use our unique algorithm to develop self-care programs for both patients and health-conscious clients to monitor their health as well as improve self-care abilities.
Predictive modelling
We use machine learning algorithms to identify high-risk patients, predict disease progression, and develop targeted interventions to improve patient outcomes. Such models will be developed into licensed programme for healthcare providers and patients for care management.
Scientific Advice
We provide scientific advisory services that support healthcare organizations in making evidence‑based decisions, enhancing treatment strategies, and aligning research with regulatory and clinical standards. Our clients include hospitals, pharmaceutical companies, insurance providers, and government agencies that aim to reinforce scientific rigor while streamlining operations. We deliver practical insights designed to advance patient outcomes, drive cost efficiency, and harness advanced analytics to foster innovation and ensure compliance across the healthcare ecosystem.
ADAMS Publications (Selected)
Pharmacovigilance Using Big Data
🫀 Cardiovascular & Statin Therapy:
- Benefits and Risks Associated with Statin Therapy for Primary Prevention in Old and Very Old Adults: Real-World Evidence from a Target Trial Emulation Study
Xu W, Lee AL, Lam CLK, Danaei G, Wan EYF
Annals of Internal Medicine, 2024; 177(6):701–710
doi: 10.7326/M24-0004
- Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation
Blais JE, Yan VKC, Chan EWY, Wong ICK, Wan EYF
Journal of the American College of Cardiology, 2025; 86(11):797–809
doi: 10.1016/j.jacc.2025.08.012
- Effectiveness and Safety of Using Statin Therapy for the Primary Prevention of Cardiovascular Diseases in Older Patients With Chronic Kidney Disease Who Are Hypercholesterolemic: A Target Trial Emulation Study
Xu W, Yau YK, Pan Y, Tse ETY, Lam CLK, Wan EYF
The Lancet Healthy Longevity, 2025; 6(3):10068
doi: 10.1016/S2666-7568(24)00238-1
- Myasthenia Gravis Following Statin Therapy: Evidence from Target Trial Emulation and Self-Controlled Case Series Study
Xu W, Yan VKC, Zhang Z, Fung KK, Chan KH, Lau GKK, Chui CSL, Lai FTT, Li X, Chan EWY, Wong ICK, Wan EYF
Nature Communications, 2024; 15:10317
doi: 10.1038/s41467-024-42787-6
🧠 Mental Health & Antipsychotic Safety:
- Clozapine Use and Risk of Infections in Patients with Schizophrenia in Hong Kong: A Population-Based Cohort Study
Hu Y, Tian W, Wei C, Sun Q, Song S, Zhou L, Chu RYK, Liu W, Liu B, Ng APP, Lee KCK, Lo HKY, Chang WC, Wong WCW, Chan EWY, Wong ICK, Lai FTT
The Lancet Psychiatry, 2025; 12(9):628–637
doi: 10.1016/S2215-0366(25)00201-9
- Incidence of Gynecological Cancers Following Prolactin-Increasing Antipsychotic Use: A Population Cohort Study
Lai FTT, Tian W, Hu Y, Wei C, Sun Q, Song S, Zhou L, Wei Y, Luo S, Ng APP, Chan JKN, Lo HKY, Chan EWY, Wong SSC, Chang WC
World Psychiatry, 2025; 24(3):447–448
doi: 10.1002/wps.21499
🧬 Diabetes & Risk Stratification:
- Cardiovascular Risk Thresholds for Intensifying Primary Care Encounter Frequency for Patients With Type 2 Diabetes Mellitus: A Target Trial Emulation
Xu W, Tse ETY, Tanuseputro P, Lam CLK, Wan EYF
CMAJ (Canadian Medical Association Journal), 2025; 197(32):E1024–E1033
doi: 10.1503/cmaj.241703
- Maternal Diabetes and Risk of Attention-Deficit/Hyperactivity Disorder in Offspring in a Multinational Cohort of 3.6 Million Mother–Child Pairs
Chan AY, Gao L, Hsieh MHC, Kjerpeseth LJ, Avelar R, Banaschewski T, Wong ICK
Nature Medicine, 2024; 30(5):1416–1423
doi: 10.1038/s41591-024-02917-8
🦠 COVID-19 & Infectious Disease:
- Post-COVID-19 Multimorbidity Incidence by Prior Vaccination Status in People With a Pre-Existing Comorbidity: A Population-Based Cohort Study
Liu B, Song S, Liu W, Hu Y, Wei C, Zhou L, Sun Q, Tian W, Chu RYK, Wong ICK, Hung IFN, Wan EYF, Li X, Chui CSL, Chan EWY, Wong CKH, Lai FTT
Journal of Infection, 2025; 91(3):106597
doi: 10.1016/j.jinf.2025.106597
- Comparative Effectiveness of Combination Therapy with Nirmatrelvir-Ritonavir and Remdesivir Versus Monotherapy with Remdesivir or Nirmatrelvir-Ritonavir in Patients Hospitalised With COVID-19: A Target Trial Emulation Study
Choi MH, Wan EYF, Wong ICK, Chan EWY, Chu WM, Tam AR, Yuen KY, Hung IFN
The Lancet Infectious Diseases, 2024; 24(11):1213–1224
doi: 10.1016/S1473-3099(24)00353-0
ADAMS Publications (Selected)
Population Health Epidemiology and Management
🩺 Chronic Disease Management & Risk Stratification:
- Cardiovascular Risk Thresholds for Intensifying Primary Care Encounter Frequency for Patients with Type 2 Diabetes Mellitus: A Target Trial Emulation
Xu W, Tse ETY, Tanuseputro P, Lam CLK, Wan EYF
CMAJ, 2025; 197(32):E1024–E1033
doi: 10.1111/dom.15899
- Optimizing Physician-Encounter Frequency for Type 2 Diabetes Patients in Primary Care Based on Cardiovascular Risk Assessment: A Target Trial Emulation Study
Xu W, Wang Y, Tanuseputro P, Lam CLK, Wan EYF
Diabetes, Obesity and Metabolism, 2024; 26(11):5358–5367
doi: 10.1093/eurjpc/zwaf480
- Evaluation of Hypertension-Related Complications 10 Years After Implementation of Risk Assessment and Management Programme for Hypertension (RAMP-HT): A Target Trial Emulation
Wong ZCT, Mak IL, Yu EYT, Tse ETY, Chin JY, Chao DVK, Tsui WWS, Ha TKH, Wan EYF, Lam CLK
European Journal of Preventive Cardiology, 2025; [Epub ahead of print]
doi: 10.1093/eurjpc/zwaf480
🧾 Health Services Research & Program Evaluation:
- Evaluation of the Effectiveness and Cost-Effectiveness of the Chronic Disease Co-Care (CDCC) Pilot Scheme: A Study Protocol
Mak IL, Liu KSN, Wong ZCT, Xu VYH, Yu EYT, Ha TKH, Wong WCW, Tse ETY, Chan L, Ng APP, Choi EPH, Roland M, Bishai D, Lam CLK, Wan EYF
BMC Primary Care, 2025; 26(1):73
doi: 10.1186/s12875-025-02765-6
🌍 Multimorbidity & Population Health Economic:
- Age-Specific Multimorbidity Patterns and Burden on All-Cause Mortality and Public Direct Medical Expenditure: A Retrospective Cohort Study
Hong SN, Lai FTT, Wang B, Choi EPH, Wong ICK, Lam CLK, Wan EYF
Journal of Epidemiology and Global Health, 2024; 14(3):1077–1088
doi: 10.1007/s44197-024-00256-y
ADAMS Publications (Selected)
Predictive Modelling
🧠 AI-Driven Risk Prediction & Precision Prevention:
- Development and Validation of Risk Prediction Model for Recurrent Cardiovascular Events Among Chinese: The Personalized CARdiovascular DIsease Risk Assessment for Chinese Model
Zhou Y, Lin CJ, Yu Q, Blais JE, Wa n EYF, Lee M, Wong E, Siu DCW, Wong V, Chan EWY, Lam TW, Chui W, Wong ICK, Luo R, Chui CSL
European Heart Journal – Digital Health, 2024; 5(3):363–370
doi: 10.1093/ehjdh/ztae018
- Optimizing Long Term Disease Prevention with Reinforcement Learning: A Framework for Precision Lipid Control
Zhou Y, Luo R, Blais JE, Lin Y, Yu CJ, Wan EYF, Lee EYF, Wong M, Siu DCW, Wong V, Chan EWY, Lam TW, Chui W, Wong ICK, Chui CSL
NPJ Digital Medicine, 2025; 8:553
doi: 10.1038/s41746-025-01951-1
- Development and Validation of 10-Year Risk Prediction Models of Cardiovascular Disease in Chinese Type 2 Diabetes Mellitus Patients in Primary Care Using Interpretable Machine Learning-Based Methods
Dong W, Wan EYF, Fong DYT, Tan KCB, Tsui WWS, Hui EMT, Chan KH, Fung CSC, Lam CLK
Diabetes, Obesity and Metabolism, 2024; 26(9):3969–3987
doi: 10.1111/dom.15745
